CSI Market
Sign In | Register

Acelyrin Inc (SLRN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SLRN Annual Cash Flow →
Cash flow data covering Acelyrin Inc–Mar 31 2024 offers a view into how Mar 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income-55.26
Depreciation & amortization0.11
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges2.92
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.17
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Gain Loss On Derivative Instruments Net Pretax-
Operating Lease Right Of Use Asset Amortization Expense0.32
Increase Decrease In Prepaid Expense And Other Assets Current14.21
Increase Decrease In Prepaid Expenses And Other Assets Noncurrent-0.13
Increase Decrease In Accrued Research And Development Expenses-6.32
Increase Decrease In Accrued Compensation And Other Current Liabilities-1.00
Increase Decrease In Operating Lease Liability-0.38
Increase Decrease In Severance Liability-1.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable5.04
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.64
Discontinued operations0.00
Net Cash flow from Operating Activities-38.96
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities162.49
Payments to Acquire Available-for-sale Securities, Debt-139.16
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities23.33
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-38.96
Total Cash Flow-15.62
4 historic quarters locked

Sign in to unlock the full Acelyrin Inc cash flow history.

Sign In Create Free Account

About Acelyrin Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001962918-25-000036

Figures are derived from filed reports and may be restated. Historical data is subject to revision.